What Is Compounded Semaglutide? Is It Safe?

Start with the disclosure, because everything else depends on it. PeRx prescribes compounded semaglutide with vitamin B12, prepared by a US 503A compounding pharmacy against each patient's individual prescription. It is not Ozempic, not Wegovy, not a generic of either, and it has never been evaluated by the FDA. Ozempic and Wegovy are FDA-approved products made by Novo Nordisk. Any page that lets those two things blur together, ours included, is doing something the FDA sent 30 warning letters about in March 2026. So this guide keeps them apart on purpose.

If you are weighing a $44 internet vial against a prescription, that comparison, including what a certificate of analysis can and cannot prove, is already worked through in gray-market GLP-1s vs compounded Read nextGray-Market GLP-1s vs Compounded: What Testing MissesThis page is for the person doing spreadsheet math on a $44 internet vial versus a legitimate prescription. No moralizing and no scare quotes. What the three tiers of GLP-1 supply legally are, what a certificate of analysis actually proves, what it cannot, and what each route really costs per month.Read article . This page is the definitional one: what compounding is, and what it is not.

What Compounding Actually Is

Compounding is the preparation of a medication by a licensed pharmacist, or a physician, for a specific patient, rather than the mass manufacture of a finished drug product under an FDA approval. It predates the FDA. Every pharmacy in the country did it before factory-made tablets existed, and it still fills gaps the manufactured market does not: a child who needs a liquid version of a tablet-only drug, a patient allergic to a dye in the approved product, a strength that is not sold.

Federal law recognizes two categories, named for the sections of the Food, Drug, and Cosmetic Act that created them.

503A: the per-prescription pharmacy

A 503A pharmacy is licensed by its state board of pharmacy and compounds against a valid prescription for an individually identified patient. The state board has primary day-to-day oversight; the FDA does surveillance and for-cause inspections but does not hold 503A pharmacies to the current good manufacturing practice (CGMP) rules that drug manufacturers follow. For injectable products, 503A pharmacies are expected to follow USP General Chapter <797>, the pharmacopeial standard for sterile compounding, which governs the cleanroom environment, personnel training, garbing, sterilization method, and the beyond-use date assigned to each preparation. A 503A pharmacy is not permitted to compound "regularly or in inordinate amounts" a drug that is essentially a copy of a commercially available product, a phrase that matters a great deal later in this guide.

503B: the outsourcing facility

Outsourcing facilities were created by the Drug Quality and Security Act of 2013, after a fungal meningitis outbreak traced to a Massachusetts compounder killed more than 60 people. A 503B facility registers with the FDA, is inspected by the FDA on a risk-based schedule, follows CGMP, and must report adverse events to the agency. In exchange it may compound in bulk without patient-specific prescriptions and sell to clinics and hospitals. The catch is that a 503B facility may generally only compound from a bulk drug substance if that substance is on the FDA's 503B bulks list or the finished drug is on the FDA shortage list at the time. That constraint is exactly where the 2026 news lands.

U.S. Food & Drug Administration, "Compounding and the FDA: Questions and Answers." Describes state board oversight of 503A pharmacies, FDA inspection of 503B outsourcing facilities, and the CGMP distinction. View study

Compounded Semaglutide vs Ozempic and Wegovy

The active molecule is the same. Semaglutide is a specific, patented peptide, and a compounding pharmacy buys it as an active pharmaceutical ingredient (API) from an FDA-registered supplier that files a drug master file with the agency. That is the part people mean when they say "it is the same drug." Everything around the molecule is different, and those differences are the honest answer to "is compounded semaglutide the same as Ozempic."

Two rows in that table do most of the work. The format row explains most of the safety difference: a pen has the dose built in, a vial asks a person to measure it. The FDA review row explains the legal difference: nobody outside the pharmacy has verified that a given compounded vial contains what its label says. A legitimate pharmacy has strong reasons to get that right and a license to lose if it does not, but that is a different thing from an approval.

One thing compounded semaglutide is definitely not is a generic. Generics are FDA-approved products shown to be bioequivalent to the brand, and no generic semaglutide exists in the United States as of August 2026. The March 2026 warning letters specifically called out telehealth companies that used the word "generic" or otherwise implied sameness with the approved drugs.

The B12 Question

Most compounded semaglutide sold through telehealth, PeRx's included, is co-formulated with vitamin B12 (cyanocobalamin) in the same vial. Some clinics have made a lot of that. We would rather describe it plainly.

What B12 is doing in the vial: it is a second ingredient combined with the semaglutide by the pharmacy, so that a person who is also prescribed B12 gets it in one injection instead of two. What B12 is not doing: there is no published controlled study, as of August 2026, showing that adding cyanocobalamin to semaglutide changes nausea, weight outcomes, energy, or anything else about how the semaglutide behaves. Claims that it "reduces side effects" or "boosts results" are marketing, and they are the kind of unsubstantiated claim the FDA has been writing letters about. PeRx does not make them, and if a glycine base suits a patient better than B12, that is available too.

There is also a regulatory wrinkle that clinics rarely mention. In its shortage-resolution notice, the FDA gave semaglutide-plus-B12 as its worked example of a combination it may still consider "essentially a copy" of the approved product, when the route of administration is the same and the strengths are within 10 percent of commercially available products, unless the prescriber documents a significant difference for that patient. In other words, B12 in the vial does not by itself make the compounded product legally distinct. What makes a 503A prescription legitimate is the prescriber's patient-specific determination, not the additive. We think patients should know that, because a clinic that sells B12 as the reason its product is allowed is telling you something that is not quite true.

U.S. Food & Drug Administration, "FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize." Includes the "essentially a copy" criteria and the semaglutide plus vitamin B12 example. View study

The Regulatory Arc, 2022 to 2026

Compounded semaglutide exists at scale because of a shortage, and its legal footing has narrowed in steps since the shortage ended. Reading the sequence explains why answers to "is compounded semaglutide legal" that were true in 2024 are wrong now.

What the April 2026 proposal does, if finalized, is close the 503B route for semaglutide almost completely. A 503B facility could no longer compound it from bulk API, because the substance would be off the bulks list and the drug is no longer in shortage. The proposal does not directly regulate 503A pharmacies. The FDA's own press release frames the distinction as "clinical need" versus economic need: the fact that compounded semaglutide is cheaper than Wegovy is not, in the agency's view, a clinical reason to compound it.

U.S. Food & Drug Administration, press announcement, April 30, 2026: "FDA Proposes to Exclude Semaglutide, Tirzepatide, and Liraglutide on 503B Bulks List." Comment docket open through June 29, 2026. View study

U.S. Food & Drug Administration, press announcement, March 3, 2026: "FDA Warns 30 Telehealth Companies Against Illegal Marketing of Compounded GLP-1s." View study

So what remains permitted, and what does it require?

As of August 2026, a state-licensed 503A pharmacy may still compound semaglutide for an individual patient where the prescription reflects a prescriber's determination that the compounded product differs from the approved one in a way that matters for that patient. The FDA has also said it does not intend to act against a compounder filling four or fewer prescriptions of an essentially-a-copy product in a calendar month, a carve-out designed for occasional need, not for a telehealth business model. What that requires of a clinic is uncomfortable but simple: a real clinical review, a real reason on the record, and no pretending the product is the brand. This is a compliance posture, not a legal guarantee. The regulatory picture has changed roughly once a year since 2023, and it may change again.

The Salt-Form Problem

Semaglutide the drug is the base form of the molecule. Chemically, a peptide can also be supplied as a salt, such as semaglutide sodium or semaglutide acetate, which is often cheaper and easier to source because it is sold for laboratory rather than pharmaceutical use. The FDA has been explicit: these salts are different active ingredients from the one in the approved drugs, the agency has no data on whether they behave the same way in the body, and it "is not aware of any lawful basis for their use in compounding." Several state boards have echoed the warning.

For a patient, the practical question is what the pharmacy started with. A pharmacy that sources semaglutide base from an FDA-registered API supplier with a drug master file is doing the thing the law contemplates. A seller whose product lists "semaglutide sodium" or "semaglutide acetate," or who cannot tell you the API source at all, is on the wrong side of an FDA statement that has been standing since 2023. You are entitled to ask your pharmacy this question directly; a legitimate one will answer.

U.S. Food & Drug Administration, "FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss." Salt-form statement and adverse event totals as of May 31, 2026. View study

What the Adverse Event Numbers Say

As of May 31, 2026, the FDA had received 990 adverse event reports associated with compounded semaglutide and more than 730 associated with compounded tirzepatide. Three things about those numbers are worth holding at once.

First, they are almost certainly an undercount. Federal law does not require 503A pharmacies to submit adverse events to the FDA, so the reports that exist come mostly from patients, clinicians, and 503B facilities. Second, the FDA itself notes that many of the reported events are consistent with the known side effect profile of the approved drugs: nausea, vomiting, diarrhea, abdominal pain, constipation. Those are semaglutide effects, not compounding effects. Third, the failure mode that is specific to compounding is dosing error. The FDA has documented hospitalizations from patients drawing the wrong volume from a multi-dose vial, sometimes by several-fold, and from prescribers miscalculating a conversion between milligrams and units.

A 2026 analysis of US poison center data found GLP-1 exposure calls rose sharply after the drugs were approved for weight management, with a meaningful share involving dosing errors (Miller et al., Journal of Medical Toxicology, 2026). That is the risk a vial format carries and a pen format mostly does not, and it is why the units math in where to inject semaglutide and tirzepatide Read nextWhere to Inject Semaglutide and TirzepatideBoth are once-weekly subcutaneous injections, and the three standard sites are the same for each. The part that trips people up is not the site. It is that a compounded vial is not a prefilled pen, so you are drawing your own dose and reading it in syringe units. Here is the practical version.Read article is worth reading slowly before a first dose.

Miller J, Miller R, Varney SM, Han D. "National Poison Center Trends in GLP-1 Receptor Agonist Exposures Following FDA Approval for Weight Loss." Journal of Medical Toxicology, 2026. PMID 41634285. View study

What a Legitimate Prescription Looks Like

The single most useful thing a patient can do is look at the label and the paperwork. A compounded prescription that was actually prepared for you under 503A carries specific, checkable markers.

The general version of this checklist, covering any peptide and any telehealth clinic, is in how to choose a telehealth peptide provider Read nextHow to Choose a Telehealth Peptide ProviderThe peptide space is full of operators who look clinical and are anything but. A slick site and a checkout button tell you nothing about who reviewed your health history, where the vial was made, or whether anyone tested what is inside it. This is the honest buyer's checklist: the green flags that mean a provider is real, the red flags that should end the conversation, and how to tell them apart before you hand over a card.Read article . And if you are being handed a certificate of analysis as a substitute for those markers, how to read a peptide COA Read nextHow to Read a Peptide COAA Certificate of Analysis is the lab report behind a peptide vial. Learn to read one line by line: identity, purity, net peptide content, sterility, and endotoxin. Then learn the red flags that separate a real prescription COA from the screenshot a gray-market vendor pastes into a product page.Read article explains what that document does and does not tell you.

How PeRx Does It

Since this guide has spent two thousand words describing what a compliant compounded semaglutide program has to look like, it is fair to describe ours against the same standard, including where it is limited.

The sequence: you complete an online intake, a licensed provider reviews it, and if semaglutide is appropriate for you, your PeRx provider will prescribe a protocol and send the prescription to the pharmacy. Your card is saved at checkout but charged only if the provider approves. The vial that arrives has your name on it, the pharmacy's name on it, and the prescriber's name on it, which is the whole point of the previous section.

Why it is a subscription when nothing else at PeRx is: because semaglutide dosing is stepped, starting at the lowest concentration and rising over months, and a clinician needs to see how the current cycle went before deciding whether the next vial is the same strength or a higher one. A 28-day cadence with a check-in before each refill is how that decision gets made by a prescriber rather than by a patient guessing. You do not choose the strength at checkout. The reasons a person might stay at a low or middle step for a long time are covered in GLP-1 maintenance dosing and microdosing Read nextGLP-1 Microdosing: Safety, Evidence, and Maintenance"Microdosing Ozempic" went from a forum phrase to a TikTok trend to a survey statistic: as of 2026, about 15% of injectable GLP-1 users say they have tried it, and nearly half of them did it without asking a doctor. Meanwhile the person who actually reached goal weight on semaglutide or tirzepatide still gets two contradictory answers about maintenance. This page covers both: what microdosing means, why it spread, what evidence exists for sub-label doses (almost none), the difference between a prescriber-set lower dose and splitting a vial yourself, and why the dose belongs on a prescription rather than in a spreadsheet.Read article .

If you are deciding between semaglutide and tirzepatide, semaglutide vs tirzepatide Read nextSemaglutide vs Tirzepatide: Which One Fits YouPeRx prescribes two compounded GLP-1 medications, one at $249 a month and one at $399. This is the decision guide we wish existed: what each molecule does, how the approved brands differ on their FDA labels, what the head-to-head research on those brands actually shows, and the questions a prescriber weighs before picking one for a specific patient.Read article compares the two compounded options PeRx offers, and the product page for compounded semaglutide has the full dosing progression and side-effect list. Anyone still deciding whether a prescription route is worth it over an internet vial should read is it safe to buy peptides online Read nextIs It Safe to Buy Peptides Online?The honest answer is that it depends entirely on the source. "Buying peptides online" covers two opposite things: unregulated research-chemical websites, and licensed telehealth backed by a real provider and an FDA-regulated pharmacy. One of those is safe. This guide shows you how to tell them apart.Read article first.

The honest limits

PeRx's semaglutide is not FDA approved, and no trial has ever tested this specific preparation. The published outcome data for semaglutide belongs to the approved drugs, and we do not borrow it. The B12 in the vial is a co-formulated ingredient and nothing more. The compounded product costs $249 a month because it is compounded, not because it has been shown to do anything the brand does not. The regulatory position of 503A semaglutide compounding depends on prescriber-documented patient need, and the FDA could narrow that further at any time, which would affect our ability to offer it. And a vial format asks you to measure a dose that a pen would measure for you. If any of those limits is a dealbreaker, the approved products exist, and the right move is to ask a prescriber about them.

Common Questions